Obstructive sleep apnea syndrome (OSAS) is definitely considered one of the major health issues in the Western world. Besides the problems with daily life functioning, such as hypersomnolence, decreased cognitive functions, motor vehicle crashes, and reduced quality of life, the most relevant medical issue is related to the strong association of OSAS with cardiovascular, cerebrovascular, and metabolic diseases.1
Several studies1–3 have pointed out that OSAS is an independent risk factor for almost all cardiovascular diseases, such as atrial fibrillation, congestive heart failure, coronary atherosclerosis, myocardial infarction, and sudden death. Namely, the last Joint National Committee report4 for prevention and treatment of hypertension considered OSAS as the first identifiable cause of hypertension. Being the prevalence of this syndrome is so high in the general population, correct therapeutic strategies are important.